In the lead-up to BIO, Cartherics’ COO, Dr Ian Nisbet was interviewed by BioSpectrum Asia to discuss the company’s innovative approach to cell therapy development. He discusses the transformative potential of CAR-NK cell therapies in treating solid tumours and endometriosis. These engineered natural killer cells, derived from iPSCs, are designed to target and eliminate cancer […]
Cartherics is delighted to be featured in the June 2025 issue of Pharma Technology Focus, drawing attention to our innovative approach to cell therapy. Unlike traditional cell therapies, Cartherics employs gene-edited natural killer (NK) cells derived from induced pluripotent stem cells (iPSCs) from umbilical cord blood.
This approach aims to enhance the immune system’s […]
Melbourne, Australia, 28 May 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, announced today that Dr. Ian Nisbet, […]
Cartherics’ appointment of Laurence Nore underscores a growing trend with global implications.
As global demand for biotechnology products and services continues to grow, innovation in the industry is becoming increasingly globalised. Cartherics Pty Ltd, a Melbourne-based biotech company pioneering cell-based immunotherapies, recently announced the appointment of U.S. life sciences executive Laurence Nore to […]
Prof. Alan Trounson, AO
Women’s health has suffered long-term disappointments in targeted research and the key funding that needs to be committed to making progress at the level we should expect. Ovarian cancer and endometriosis are two critical women’s health issues with devastating effects and neither has attracted the attention of significant resources to make acceptable […]
Today on World Ovarian Cancer Day, we are proud to share the powerful story of Heather Hawkins – ovarian cancer survivor, global marathon runner, patient advocate, and a valued Board Advisor at Cartherics.
After being diagnosed with ovarian cancer in 2007, Heather transformed her experience into a mission of awareness, action, and hope. Her survivorship, combined […]
Melbourne, Australia, 16 April 2025 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company focused on developing immune cell therapies for cancer and other diseases, is pleased to announce the appointment of Prof. Bryan R.G. Williams […]
Cartherics is pleased to announce that it has made several strategic new appointments to enhance its scientific and manufacturing teams, aligning with the company’s commitment to advancing its growing pipeline of innovative therapies. These new additions are expected to bring in diverse expertise, reinforcing the company’s capabilities in both research and development as well […]
Cartherics’ CEO, Prof. Alan Trounson, recently contributed to an insightful article in The Weekend Australian, exploring the latest advancements in cell therapy treatments for cancer. We would like to extend our thanks to Natasha Robinson for her thorough and thought-provoking piece that highlights how cell therapy breakthroughs are offering new hope to cancer […]
As Ovarian Cancer Awareness Month draws to a close, the Cartherics team gathered for an afternoon dedicated to raising awareness and funds for ovarian cancer research.
Each year, around 1,800 new ovarian cancer cases are diagnosed in Australia, with over 70% of these being at advanced stages and offering limited treatment options. Cartherics is developing innovative […]
Cartherics’ mission is the development of novel, immune cell therapy products for the treatment of cancer, endometriosis and Alzheimer’s disease.
Stay informed about our latest news and developments
© Copyright 2022 | Cartherics Pty ltd
